98%
921
2 minutes
20
While drug combinations are increasingly important in disease treatment, predicting their therapeutic interactions remains challenging. This review systematically analyzes computational methods for predicting drug combination effects through multi-omics data integration. We comprehensively assess key algorithms including DrugComboRanker and AuDNNsynergy, and evaluate integration approaches encompassing kernel regression and graph networks. The review elucidates artificial intelligence applications in predicting drug synergistic and antagonistic effects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743742 | PMC |
http://dx.doi.org/10.1038/s41746-025-01435-2 | DOI Listing |
Sci Transl Med
September 2025
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.
Triple-negative breast cancers (TNBCs) lack predictive biomarkers to guide immunotherapy, especially during early-stage disease. To address this issue, we used single-cell RNA sequencing, bulk transcriptomics, and pathology assays on samples from 171 patients with early-stage TNBC receiving chemotherapy with or without immunotherapy. Our investigation identified an enriched subset of interferon (IFN)-induced CD8 T cells in early TNBC samples, which predict immunotherapy nonresponsiveness.
View Article and Find Full Text PDFPLoS Comput Biol
September 2025
Systems Biology and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Gene signatures predictive of chemotherapeutic response have the potential to extend the reach of precision medicine by allowing oncologists to optimize treatment for individuals. Most published predictive signatures are only capable of predicting response for individual drugs, but most chemotherapy regimens utilize combinations of different agents. We propose a unified framework, called the chemogram, that uses predictive signatures to rank the relative predicted sensitivity of different drugs for individual tumors.
View Article and Find Full Text PDFJ AOAC Int
September 2025
Analytical Development Division, Senores Pharmaceuticals, Ahmedabad, India.
Background: Molnupiravir, an FDA-approved antiviral for the treatment of COVID-19, requires reliable analytical methods to ensure its quality and safety due to its therapeutic importance.
Objectives: This study presents the development of a stability-indicating RP-HPLC method for estimating molnupiravir-related impurities in capsule formulations. An unknown impurity is structurally elucidated using LC-TQ/MS and 1H and 1³C NMR spectroscopy.
IEEE Trans Comput Biol Bioinform
September 2025
Accurately identifying associations between human genes (proteins) and clinical phenotypes is critical for advancing drug development and precision medicine. While the human phenotype ontology (HPO) standardizes clinical phenotypes, current computational approaches for predicting human protein-phenotype associations suffer from two limitations: (1) underutilization of multimodal protein-related information and (2) lack of state-of-the-art deep learning representations tailored to diverse data modalities, such as text and sequence. To overcome these limitations, we introduce MultiFusion2HPO, a novel multimodal model that integrates diverse features and advanced learning methods from multiple data sources to enhance the prediction of human protein-HPO associations.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
Department of Zoology and Biodiversity Research Centre, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Organisms often face multiple selective pressures simultaneously (e.g., mine tailings with multiple heavy metal contaminants), yet we know little about when adaptation to one stressor provides cross-tolerance or cross-intolerance to other stressors.
View Article and Find Full Text PDF